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The human commensal yeast Candida is the fourth most common cause of
hospital-acquired bloodstream infections, with Candida albicans accounting for the
majority of the >400,000 life-threatening infections annually. Diagnosis of invasive
candidiasis (IC), a disease encompassing candidemia (blood-borne yeast infection)
and deep-seated organ infections, is a major challenge since clinical manifestations
of the disease are indistinguishable from viral, bacterial and other fungal diseases,
and diagnostic tests for biomarkers in the bloodstream such as PCR, ELISA, and
pan-fungal β-D-glucan lack either standardization, sensitivity, or specificity. Blood culture
remains the gold standard for diagnosis, but test sensitivity is poor and turn-around
time slow. Furthermore, cultures can only be obtained when the yeast resides in the
bloodstream, with samples recovered from hematogenous infections often yielding
negative results. Consequently, there is a pressing need for a diagnostic test that
allows the identification of metastatic foci in deep-seated Candida infections, without
the need for invasive biopsy. Here, we report the development of a highly specific
mouse IgG3 monoclonal antibody (MC3) that binds to a putative β-1,2-mannan
epitope present in high molecular weight mannoproteins and phospholipomannans
on the surface of yeast and hyphal morphotypes of C. albicans, and its use as
a [64Cu]NODAGA-labeled tracer for whole-body pre-clinical imaging of deep-seated
C. albicans infections using antibody-guided positron emission tomography and
magnetic resonance imaging (immunoPET/MRI). When used in a mouse intravenous
(i.v.) challenge model that faithfully mimics disseminated C. albicans infections in
humans, the [64Cu]NODAGA-MC3 tracer accurately detects infections of the kidney, the
principal site of blood-borne candidiasis in this model. Using a strain of the emerging
human pathogen Candida auris that reacts with MC3 in vitro, but which is non-infective
in i.v. challenged mice, we demonstrate the accuracy of the tracer in diagnosing
invasive infections in vivo. This pre-clinical study demonstrates the principle of using
antibody-guided molecular imaging for detection of deep organ infections in IC, without
the need for invasive tissue biopsy.
Keywords: monoclonal antibody, computed tomography scanning, invasive candidiasis, MRI imaging, positron
emission tomography, invasive fungal disease
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INTRODUCTION
Infectious diseases are a leading cause of death worldwide, with
fungi accounting for an estimated two million life-threatening
infections each year (Brown et al., 2012). At present, diagnostic
tests that can accurately detect and differentiate infectious
organisms are lacking, resulting in the incorrect use of
antimicrobial drugs, and emergence of antibiotic and antifungal
resistance. Non-invasive molecular imaging holds enormous
potential for tracking infectious diseases (Santangelo et al.,
2015; Rolle et al., 2016; Wiehr et al., 2016; Davies et al.,
2017), but conventional radiological imaging modalities such as
computed tomography (CT) and magnetic resonance imaging
(MRI), while producing high contrast images of all structures
within the human body, rely on structural abnormalities
in tissues and organs to differentiate between infectious
and non-infectious pathologies (Thornton, 2018). In contrast,
molecular imaging is able to deliver highly specific and sensitive
antibody-guided imaging of viral (Santangelo et al., 2015),
bacterial (Wiehr et al., 2016), and fungal diseases (Rolle et al.,
2016; Davies et al., 2017) in animal models of disease, with real
potential for translation to the clinical setting (Davies et al.,
2017).
Invasive candidiasis (IC) is a life-threatening disease caused
by the genus Candida. The disease, which encompasses both
candidemia (bloodstream yeast infection) and deep-seated
candidiasis (infection of the tissues beneath mucosal
surfaces) (Clancy and Nguyen, 2013), can occur following
gastrointestinal surgery, which allows the fungus to penetrate
the mucosa (Vincent et al., 2014), while neutropenia, caused
by chemotherapy or by immunosuppression of solid-organ or
hematological stem cell transplant patients, impairs immune
system recognition, and clearance of Candida cells leading
to disseminated infections (Safdar and Armstrong, 2011). An
estimated 400,000 cases of Candida bloodstream infection
occur globally each year (Brown et al., 2012), making up
∼3% of all nosocomial infections in Europe, and ∼12% in
the United States (Schmiedel and Zimmerli, 2016). IC is
now the fourth most common bloodstream infection, behind
staphylococcal and enterococcal infections, although IC carries
much higher rates of mortality (Wisplinghoff et al., 2004; Lewis,
2009).
While non-albicans Candida species have emerged as
pathogens of immuno-compromised individuals over recent
years (Chi et al., 2011; Papon et al., 2013; Pfaller et al.,
2014), Candida albicans remains the most common cause of
mucosal and systemic infections and is responsible for up
to 70% of cases worldwide (Diekema et al., 2012; Guinea,
2014). Early detection of the pathogen is critical for prompt
and effective treatment with antifungal drugs. The current
“gold-standard” for detection relies on culture of the fungus
from blood, but blood cultures are positive in only 50–70% of
cases, are slow to perform, and are rarely positive in patients
with deep-seated candidiasis (Clancy and Nguyen, 2013). While
non-culture based assays that detect Candida nucleic acids,
fungal β-D-glucan, and Candida mannan antigen (Mn) and
anti-mannan antibodies (A-Mn) in patient sera offer potential
advantages over culture (Ellis et al., 2009; Avni et al., 2011;
Jaijakul et al., 2012), they have their own inherent weaknesses in
specificity and sensitivity, and are unable to identify metastatic
foci in deep-seated Candida infections (Clancy and Nguyen,
2013).
Positron emission tomography and magnetic resonance
imaging (PET/MRI) is an immensely powerful tool for
diagnosing cancer, but its use in detecting microbial infections
is still in its infancy. Despite this, we have recently shown
the enormous potential of immunoPET/MRI for imaging
of invasive pulmonary aspergillosis (IPA), a lung disease of
immuno-compromised humans caused by the ubiquitous
air-borne mold Aspergillus fumigatus (Rolle et al., 2016; Davies
et al., 2017; Thornton, 2018). In the present study, we set out
to determine whether a newly developed Candida-specific
monoclonal antibody (mAb) (MC3), when conjugated to [64Cu]
using the chelator 2,2′-(7-(1-carboxy-4-((2,5-dioxopyrrolidin-
1-yl)oxy)-4-oxobutyl)-1,4,7-triazonane-1,4-diyl) diacetic acid
(NODAGA), could be used as a disease-specific tracer in
immunoPET/MRI to detect deep-seated C. albicans infections
in vivo following bloodstream infection. We show, using an
intravenous (i.v.) challenge model of IC which faithfully mimics
disseminated C. albicans infection in humans (MacCallum
and Odds, 2005; Conti et al., 2014), the accuracy of the
[64Cu]NODAGA-MC3 tracer in detecting deep organ infections,
and demonstrate that antibody-based immunoPET can be used
successfully to non-invasively identify this problematic disease
in vivo.
MATERIALS AND METHODS
Ethics Statement
Hybridoma work described in this study was conducted under
a UK Home Office Project Licence and was reviewed by the
institution’s Animal Welfare Ethical Review Board (AWERB)
for approval. The work was carried out in accordance with The
Animals (Scientific Procedures) Act 1986 Directive 2010/63/EU
and followed all the Codes of Practice which reinforce this law,
including all elements of housing, care, and euthanasia of the
animals. All animal molecular imaging work was performed
in the Department of Preclinical Imaging and Radiopharmacy
(Werner Siemens Imaging Center, Eberhard Karls University
of Tübingen, Germany), and was carried out according to
protocols approved by the Regierungspräsidium Tübingen
(Permit Number: R9/16) as per guidelines from the European
Health Law of the Federation of Laboratory Animal Science
Associations (FELASA).
Fungal Cultures
Fungi used for antibody specificity tests were grown on slopes of
Sabouraud dextrose agar [SDA; SD broth (S3306, Sigma), agar
(MC006, Neogen) 20 g/L], glucose-peptone-yeast extract agar
{GPYA; GPY medium [glucose 40 g/L, bacteriological peptone
(LP0037, Oxoid) 5 g/L, yeast extract 5 g/L] containing agar
15 g/L}, or potato dextrose agar [PDA; potato dextrose broth
(P6685, Sigma), agar 20 g/L]. All media were autoclaved at 121◦C
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for 15 min prior to use and fungi were grown at 26◦C under a
16 h fluorescent light regime.
Preparation of Immunogen and
Immunization Regime
Candida albicans strain SC5314 was chosen for hybridoma
development as it belongs to the predominant clade of closely
related C. albicans strains that represents almost 40% of
all isolates worldwide, as determined by DNA fingerprinting
and multi-locus sequence typing (Soll and Pujol, 2003).
Three-day-old GPYA Petri dish cultures of C. albicans SC5314
grown at 26◦C were flooded with 20 mL of sterile Milli-Q
water (MQ-H2O) and the suspended cells snap frozen in liquid
N2, lyophilised and placed at −20◦C for long-term storage.
Immunogen was prepared by re-suspending lyophilised cells in
sterile filtered phosphate-buffered saline (PBS; 137 mM NaCl,
2.7 mM KCl, 8 mM Na2HPO4, and 1.5 mM KH2PO4, pH
7.2) and 2 mg/mL suspensions heat-inactivated by placing at
55◦C for 45 min. The immunogen was stored at −20◦C before
animal immunisations. For immunisations, four 6-week-old
BALB/c white female mice (Charles River) were each given four
intra-peritoneal injections (300 µL per injection) of immunogen
at 2-week intervals and a single booster injection was given 5 days
before fusion.
Production and Screening of
Hybridomas and Determination of
Antibody Specificities
Hybridoma cells were produced by the method described
elsewhere (Thornton, 2001) and mAb-producing clones
identified in ELISA tests by using soluble antigens from the
C. albicans SC5314 immunogen immobilized to the wells
of Nunc F96 Maxisorp microtiter plates (442402, Thermo
Fisher Scientific) at 50 µL/well. Positive cell lines were tested
for mAb specificities against surface washings from replicate
SDA slope cultures of yeast, yeast-like, and filamentous fungi
(Supplementary Table S1) prepared as described elsewhere
(Thornton, 2001). Specificities of Candida-specific mAbs were
then further tested using antigen solutions prepared from SDA
Petri dish culture plates inoculated with cell suspensions of
the human pathogenic yeasts C. albicans (SC5314), Candida
glabrata (CBS4962), Trichosporon asahii var. asahii (CBS5286),
or Cryptococcus neoformans (CBS7779), either as single species
cultures or as mixed species cultures (Supplementary Figure S1).
After 24 h incubation at 26◦C, antigen solutions were prepared
by flooding the plates with 10 mL PBS, suspending cells
using sterile L-shaped spreaders, and pelleting of cells by
centrifugation at 14,500 rpm for 5 min. Protein concentrations,
determined spectrophotometrically at 280 nm (Nanodrop;
Agilent Technologies), were adjusted to 60 µg/mL and 50 µL
volumes were used to coat the wells of microtiter plates, which
were incubated overnight at 4◦C. Wells were washed three times
with PBST (PBS containing 0.05% (v/v) Tween-20), once with
PBS and once with dH2O before being air-dried at 23◦C in a
laminar flow hood. The plates were sealed in plastic bags and
stored at 4◦C in preparation for assay by ELISA.
Enzyme-Linked Immunosorbent Assay
Wells containing immobilized antigens were incubated for
15 min with 200 µL of PBS containing 1.0% (w/v) bovine serum
albumin (BSA; A7906, Sigma) as a blocker. After a 5-min rinse
with PBS, wells were incubated with 50 µL of mAb hybridoma
tissue culture supernatant (TCS) for 1 h, after which wells
were washed three times, for 5 min each, with PBST. Goat
anti-mouse polyvalent immunoglobulin (G, A, M) peroxidase
conjugate (A0412, Sigma), diluted 1:1000 in PBST containing
0.5% (w/v) BSA, was added to the wells and incubated for a
further hour. The plates were washed with PBST as described,
given a final 5 min wash with PBS, and bound antibody visualized
by incubating wells with 3,3′,5,5′ Tetramethylbenzidine (T2885,
Sigma) substrate solution (Thornton, 2001) for 30 min, after
which reactions were stopped by the addition of 3 M H2SO4.
Absorbance values were determined at 450 nm using a microplate
reader (Tecan GENios, Tecan Austria GmbH). Control wells
were incubated with tissue culture medium (TCM) containing
10% (v/v) fetal bovine serum (FBS; FCS-SA, Labtech) only.
All incubation steps were performed at 23◦C in sealed plastic
bags. The threshold for detection of the antigen in ELISA was
determined from control means (2× TCM absorbance values)
(Sutula et al., 1986). These values were consistently in the range
of 0.050–0.100. Consequently, absorbance values >0.100 were
considered as positive for the detection of antigen.
Determination of Ig Class and
Sub-Cloning Procedure
The Ig class of mAbs was determined by using antigen-mediated
ELISA (Thornton, 2001). Wells of microtiter plates coated with
water-soluble antigens from surface washing of C. albicans
SC5134 were incubated successively with hybridoma TCS for 1 h,
followed by goat anti-mouse IgG1, IgG2a, IgG2b, IgG3, IgM, or
IgA-specific antiserum (ISO-2, Sigma) diluted 1:3000 in PBST
for 30 min, and rabbit anti-goat peroxidase conjugate (A5420,
Sigma) diluted 1:1000 for a further 30 min. Bound antibody was
visualized with TMB substrate as described. Hybridoma cell lines
were sub-cloned three times by limiting dilution, and cell lines
were grown in bulk in a non-selective medium, preserved by
slowly freezing in FBS/dimethyl sulfoxide (92:8 v/v), and stored
in liquid N2.
Epitope Characterization by Heat,
Chemical, and Enzymatic Modification
Heat stability of antigens was investigated by placing surface
washings of C. albicans SC5134 in a boiling water bath. At
10 min intervals over a 60 min period, 1 mL samples were
removed, cooled, and centrifuged at 14,500 rpm for 5 min. Fifty
microliters volumes of supernatants were immobilized to the
wells of microtiter plates for assay by ELISA as described. For
periodate oxidation, microtiter wells coated with soluble antigens
in surface washings were incubated with 50 µL of sodium
meta-periodate solution (20 mM NaIO4 in 50 mM sodium acetate
buffer, pH 4.5) or acetate buffer only (control) for 24, 4, 3, 2,
1, or 0 h at 4◦C in sealed plastic bags. Plates were given four
3 min PBS washes before processing by ELISA as described.
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For protease digestions, microtiter wells containing immobilized
antigens were incubated with 50 µL of a 0.9 mg/mL solution of
pronase (protease XIV; P5147, Sigma), trypsin solution (1 mg/mL
in MQ-H2O), or PBS and MQ-H2O only (controls) for 4 h at 37
or 4◦C. Plates were given four 3 min rinses with PBS and then
assayed by ELISA as described.
Purified Candida albicans Cell Wall
Mannan
Candida albicans cell wall mannans, purified by the method
of Longbottom et al. (1976), were obtained from the National
Institute for Biological Standards and Control (catalog no.
76/515). The lyophilised material was re-suspended in MQ-H2O
to create a 1 mg/mL stock solution, which was stored at −20◦C
prior to use. A sample of the mannan stock was diluted 1:2 (v:v)
with PBS and then double diluted in PBS across the wells of
microtiter plates at 50 µL per well. ELISA was then performed
as described. For western blotting studies, the mannan stock was
diluted in Laemmli buffer (Laemmli, 1970) and denatured by
heating at 95◦C for 10 min.
Candida albicans Mannan Mutants
Candida albicans wild-type strains SC5134 and NGY152, and
mannan mutants of NGY152 [1pmr1, 1och1, 1mnn4, and
1mnt1,2 (Hall and Gow, 2013)], were grown on SDA slopes for
3 days and surface washings containing water-soluble antigens
prepared using sterile MQ-H2O as described. Surface washings
were centrifuged for 5 min at 14,500 rpm, and supernatant
protein concentrations determined spectrophotometrically at
280 nm were adjusted to 60 µg/mL using PBS. Fifty-µL volumes
were used to coat the wells of microtiter plates, which were
assayed by ELISA as described. For western blotting, surface
washings were diluted in Laemmli buffer, and denatured by
heating at 95◦C for 10 min.
To investigate shedding of extracellular antigen
(Supplementary Figure S2), wild-type and mutant strains
of C. albicans were grown as SDA slope cultures for 3 days, and
yeast cell suspensions prepared as described. After washing with
sterile MQ-H2O, cell suspensions were adjusted to 103 cells/mL,
before 1 mL volumes were added to replicate flasks containing
100 mL of autoclaved GPY medium. Cultures were shaken
(125 rpm) at 26◦C and, after 3 days, the fluids were removed
and centrifuged at 14,500 rpm. Fifty-µL samples of supernatants
containing 60 µg protein/mL were used to coat the wells of
microtiter plates, which were assayed by ELISA as described. For
western blotting, culture fluids were diluted in Laemmli buffer
and denatured by heating at 95◦C for 10 min.
Polyacrylamide Gel Electrophoresis and
Western Blotting
Sodium dodecyl sulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) was carried out using 4–20% gradient
polyacrylamide gels (161-1159, Bio-Rad) under denaturing
conditions. Proteins were separated electrophoretically at
165 V and pre-stained markers (161-0318, Bio-Rad) were used
for molecular weight determinations. For western blotting,
separated proteins were transferred electrophoretically
onto a PVDF membrane (162-0175, Bio-Rad) for 2 h at
75 V, and the membrane was blocked for 16 h at 4◦C with
PBS containing 1% (w/v) BSA. Blocked membranes were
incubated with hybridoma TCS diluted 1:2 (v/v) with PBS
containing 0.5% (w/v) BSA (PBSA) for 2 h at 23◦C. After
washing three times with PBS, membranes were incubated
for 1 h with goat anti-mouse IgG (whole molecule) alkaline
phosphatase conjugate (A3562, Sigma), diluted 1:15,000 in
PBSA. Membranes were washed three times with PBS, once
with PBST and bound antibody visualized by incubation
in substrate solution (Thornton, 2008). Reactions were
stopped by immersing membranes in dH2O, and membranes
were then air dried between sheets of Whatman filter
paper.
Immunofluorescence
Microscope slides were sterilized by autoclaving and coated with
washed SC5314 cells suspended in 1% (w:v) glucose solution
for blastospore production, or in 20% (v:v) FBS to induce the
formation of hyphae. The slides were incubated in a moist
chamber at 26◦C for 16 h (blastospore production) or at 37◦C
for 5 h (hyphal induction). After air-drying, the cells were
fixed according to the method described elsewhere (Thornton,
2001). Fixed cells were incubated with hybridoma TCS for
1 h, followed by three 5 min rinses in PBS. Samples were
then incubated with goat anti-mouse polyvalent fluorescein
isothiocyanate (FITC) conjugate (F1010, Sigma), diluted 1:40
in PBS, for 30 min. They were given three 5-min washes with
PBS and mounted in PBS-glycerol mounting medium (F4680,
Sigma) before overlaying with coverslips. All incubation steps
were performed at 23◦C, in a moist environment to prevent
evaporation, and slides were stored in the dark, at 4◦C, prior
to examination using an epifluorescence microscope (Olympus
IX81) fitted with 495 nm (excitation) and 518 nm (emission)
filters for FITC.
Purification of mAb MC3
Hybridoma TCS was harvested by centrifugation at 2147 g
for 40 min at 4◦C, followed by filtration through a 0.8 µM
cellulose acetate filter (10462240, GE Healthcare Life Sciences,
United Kingdom). Culture supernatant was loaded onto a HiTrap
Protein A column (17-0402-01, GE Healthcare Life Sciences)
using a peristaltic pump P-1 (18-1110-91, GE Healthcare
Life Sciences) with a low pulsation flow of 1 mL/min.
Columns were equilibrated with 10 mL of PBS, and column-
bound antibody was eluted with 5 mL of 0.1 M glycine-
HCl buffer (pH 2.5) with a flow rate of 0.5 mL/min.
The buffer of the purified antibody was exchanged to PBS
using a disposable PD-10 desalting column (17-0851-01, GE
Healthcare Life Sciences). Following purification, the antibody
was sterile filtered with a 0.24 µm syringe filter (85037-574-44,
Sartorius UK Ltd., United Kingdom) and stored at 4◦C. Protein
concentration was determined using a spectrophotometer,
and purity was confirmed by SDS-PAGE and gel staining
using Coomassie Brilliant Blue R-250 dye (Thermo Fisher
Scientific).
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Conjugation of mAb MC3
Protein A-purified mAb MC3 was buffered with 0.1 M sodium
carbonate (pH 9, Chelex-treated) using an Amicon Ultra-15 filter
unit (30 kDa MWCO, Merck Millipore, Darmstadt, Germany).
Twenty molar equivalents of chelator p-NCS-Bz-NODAGA
(Chematech, Dijon, France) were reacted with the antibody
for 60 min at room temperature, with subsequent antibody
purification via an Amicon Ultra-15 filter using Chelex-treated
0.25 M sodium acetate (pH 6). This protocol typically yields
1–3 chelators per antibody. Elution profile in High Pressure
Size Exclusion Chromatography (HPSEC, Phenomenex BioSep
SEC-s3000 300 × 4.6 mm, 1.5 mL/min PBS with 50 mM EDTA)
was not discernible from the unconjugated antibody.
PET Tracer Production and Radiolabeling
of NODAGA-MC3 Conjugate
64Cu was produced at the in-house radiopharmacy of the
Department of Preclinical Imaging and Radiopharmacy in
Tübingen, using a PETtrace cyclotron (General Electric Medical
Systems). 64Cu was generated by 12.5 MeV proton irradiation
of enriched 64Ni metal (35–75 mg; Isoflex, >98% enrichment)
electroplated on a platinum/iridium disk via the 64Ni(p,n)64Cu
nuclear reaction as described previously (Alt et al., 2010). In
brief, 64Cu was separated from the bulk nickel target and
other metallic impurities by acid dissolution followed by anion
exchange chromatography (AG1 × 8, Bio-Rad) in aqueous
hydrochloric acid media (Trace Select, Sigma-Aldrich). The
fractions containing the 64Cu product were dried under argon at
120◦C.
For antibody radiolabeling, the dry 64CuCl2 was re-dissolved
in 0.1 M HCl and the pH was adjusted to 5–6 using
0.5 M ammonium acetate. 1.3 µg of p-NCS-benzyl-NODAGA
conjugated MC3 antibody was added per MBq of 64Cu and
incubated at 42◦C for 60 min. Thin layer chromatography
(Polygram SIL G/UV254, Macherey-Nagel, Düren, Germany,
mobile phase: 0.1 M sodium citrate, pH 5.0) and radio-HPSEC
(as described above) were conducted for quality control of
the radiolabeled antibodies [radiochemical purity at least 95%
(TLC), HPSEC elution profile corresponding to the unmodified
antibody].
Serum Stability of the
[64Cu]NODAGA-MC3 Tracer
For serum stability tests, the radiolabeled MC3 antibody was
incubated with a threefold volume of C57BL/6 serum at 37◦C.
Samples were taken after 0, 1, 24, and 48 h and immediately
analyzed by using Instant Thin Layer Chromatography-Silica
Gel (iTLC-SG, Macherey-Nagel, Düren, Germany, mobile phase:
0.1 M sodium citrate pH 5.0) and radio-HPSEC (as described
above).
Molecular Imaging
Mouse Strain and i.v. Injections of Candida and
[64Cu]NODAGA-MC3 Tracer
The animal imaging work was carried out using mice of
the same age and sex which were injected with the same
doses of pathogen and tracer to minimize bias. Eight to
14-week-old female C57BL/6 OlaHsd mice were purchased
from Harlan Laboratories GmbH (Venray, Netherlands). The
animals were kept under standardized and sterile environmental
conditions (20 ± 1◦C room temperature, 50 ± 10% relative
humidity, 12 h light-dark cycle) and received food and water
ad libitum. For inoculum preparation, C. albicans SC5314 and
C. auris strain CBS10913 were grown on GPYA as described,
and blastospores harvested after 3 days of incubation at
37◦C by flushing cultures with sterile PBS. The spores were
washed twice by centrifugation at 400 g and re-suspension in
fresh sterile PBS. The animal infection and imaging protocol
(Supplementary Figure S3A) included simultaneous PET/MR
imaging of Candida-infected and non-infected control mice
(PBS only) at three consecutive time points [3, 24, and
48 h post-infection (p.i.)]. For administration of inoculum
and tracer, animals were anaesthetized briefly with 1.5%
isoflurane and 0.8 L/min 100% oxygen, and their lateral
tail veins injected with 20 µg of [64Cu]NODAGA-labeled
MC3 antibody (corresponding to 12–14 MBq for immunoPET
imaging), and 100 µL of blastospore suspension (or PBS
only), with each mouse receiving a total of 1 × 106
blastospores.
The severity of the infection model is low since the imaging
experiments were performed in healthy, immunocompetent
mice. The health and general well-being of the mice were
assessed daily, and body weights were measured every 24 h.
According to the animal care protocol, the health status of
the animals was assessed daily and evaluated using a score
sheet. The categories for the score sheet included mobility
of the animals, flight reaction, grooming, fur condition,
and loss of weight in %. The health status of the mice
over the course of the experiments showed no weight
loss beyond 20% or other signs which would have led to
euthanizing of the mouse. No adverse events occurred during
the time course of 2 days of infection and no or marginal
weight loss was observed in mice due to infection and/or
anesthesia.
Simultaneous PET/MRI and ex vivo
Bio-Distributions
In vivo bio-distributions of the antibody-based PET tracers
were assessed using a small animal PET insert (Bruker BioSpin
GmbH, Ettlingen, Germany) yielding a spatial resolution of
approximately 1.3 mm in the reconstructed images (Wehrl et al.,
2013). Static PET scans (10 min) were acquired 3, 24, and 48 h
after the injection of Candida inoculum and tracer. During
PET and MR imaging, the animals were anesthetized with 1.5%
isoflurane mixed with 100% oxygen. PET data were acquired
in list-mode, histogrammed in one 10 min time frame and
reconstructed using a 2D iterative ordered subset expectation
maximization (OSEM2D) algorithm. MR imaging was performed
on a 7 T, 300 MHz small animal MR tomograph (Bruker Biospin
GmbH) for the acquisition of anatomical information. The
images were acquired using a T2 fat saturated 3D sequence with
a TE/TR of 90.51/1800.000 ms. Additionally, a T1 3D fast low
angle shot (FLASH) sequence with a TE/TR of 6.000/30.000 ms
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was performed. PET images were normalized to each other,
subsequently fused to the respective MR images and analyzed
using Inveon Research Workplace software (Siemens Preclinical
Solutions, Knoxville, TN, United States). Regions of interest
(ROIs) were drawn around the respective tissues based on the
anatomical information from the MR images. The imaging data
were analyzed blinded and cross-checked by two experienced
researchers. Absolute quantification of the PET data is expressed
as percentage of the injected dose per cubic centimeter (%ID/cc).
After the final PET scan at 48 h, all animals were euthanized
by cervical dislocation under deep anesthesia and dissected.
Organs were removed and radioactivity was quantified with
an aliquot of the injected radiotracer in a γ-counter (Wallac
2480 WIZARD 3′′, PerkinElmer, Waltham, MA, United States)
using an energy window between 350 and 650 keV. The
results are expressed as % injected dose per g (%ID/g) of
tissue.
Statistical Analysis
The number of mice used in each group (N = 4–5) was
determined by power analysis to allow statistical significance
at a threshold of 5% and a power of 90%, with the average
values differing by 2 SD. For experiments with more
than two investigated groups, statistical significances were
calculated using one-way analysis of variance (ANOVA)
followed by Tukey’s multiple comparison test conducted with
Origin 8 software (OriginLab Corporation, Northampton,
MA, United States). Data were considered statistically
significant at ∗p < 0.05. Unless otherwise stated, all
quantitative data are shown as the mean ± 1 standard
deviation (SD).
RESULTS
Production of Hybridomas, Isotyping,
and mAb Specificity
A single fusion was performed and 418 hybridoma cell lines
were tested for recognition of the immunogen. The cell line
MC3 was selected for further testing based on the strength
of its reaction in ELISA and was sub-cloned three times.
Isotyping showed that MC3 belonged to immunoglobulin class
G3 (IgG3). Specificity of MC3 was determined in ELISA tests
by using antigens from a wide range of clinically relevant yeasts,
yeast-like fungi, and molds (Supplementary Table S1). It reacted
with antigens from several Candida species, the majority of
which belong to the CTG clade (C. albicans, C. dubliniensis,
C. famata, C. guilliermondii, C. lusitaniae, C. tropicalis), and
also C. auris, C. pseudotropicalis, and C. palmioleophila. It did
not react with the other Candida species tested, with a wide
range of related and unrelated yeasts, yeast-like fungi or molds
of clinical relevance (Figure 1), or with the human commensal
yeast Saccharomyces cerevisiae. No cross-reactivity was found
with antigens prepared from single or mixed-species cultures
of C. glabrata, T. asahii, or C. neoformans (Supplementary
Figure S1), further demonstrating its specificity for C. albicans
in polymicrobial cultures.
Recognition of Purified Candida albicans
Mannan
Mannan, the major carbohydrate of the Candida cell wall,
consisting of α-1-6, α-1-2, α-1-3, and β-1-2 structures (Netea
et al., 2008; Hall and Gow, 2013), was investigated as the
putative antigen bound by MC3. In ELISA tests, MC3 recognized
purified C. albicans cell wall mannan at concentrations as low
as ≥1.3 µg/mL (Figure 2A). The mAb also recognized purified
mannans with molecular weights >200 kDa (Figure 2B). This
pattern of binding is consistent with mAbs shown previously to
bind to β-1,2-mannan structures (Jouault et al., 1998; Poulain
et al., 2002). Western blot binding patterns with soluble antigens
extracted from the C. albicans SC5314 immunogen showed
strong reaction of MC3 with glycosylated antigens with molecular
weights between ∼100 and >200 kDa, and a less strong
reaction with those of lower molecular weight, between ∼50
and ∼100 kDa (Figure 2B). This staining pattern is consistent
with mAbs shown to bind to C. albicans mannan-containing
antigens (Torosantucci et al., 1991). MAb MC3 also reacted with
an antigen with a molecular weight of ∼12 kDa (Figure 2B),
which is consistent with recognition of the cell wall glycolipid
antigen phospholipomannan (PLM) (Trinel et al., 1993; Jouault
et al., 1998; Poulain et al., 2002; Mille et al., 2012). PLM contains
exclusively β-1,2-mannans, which are also found to decorate
mannoprotein structures in the C. albicans cell wall (Trinel et al.,
1999; Mille et al., 2004; Fradin et al., 2008). Taken together, these
results suggest that the epitope of MC3 comprises β-1,2-mannan
structures.
Candida albicans Mannan Mutants
The characteristics of C. albicans mannan mutants have been
published elsewhere (Bates et al., 2005; Munro et al., 2005; Hall
and Gow, 2013; Shahana et al., 2013), and show that the mutant
1och1 lacks branched outer chain N-mannan structures, the
mutant 1mnn4 lacks phosphomannan on N-branched chains,
and mutant 1mnt1,2 has truncated O-mannan. The mutant
1pmr1 differs to these other mutants in that disruption of the
PMR1 gene results in truncation of all branched N-mannan,
O-mannan, and PLM structures (Bates et al., 2005; Munro et al.,
2005; Hall and Gow, 2013). In western blotting studies, using
soluble antigens in surface washings (Figure 2C), MC3 reacted
with high molecular weight mannan-containing antigens with
a similar binding profile to that of the SC5314 immunogen
(Figure 2B). This high molecular weight binding pattern was
similar for all of the strains tested (Figure 2C). MC3 also reacted
with the ∼12 kDa antigen, assumed to be PLM, in all strains
except1pmr1 (marked with asterisk in Figure 2C).
Shedding of antigens by C. albicans strains SC5134 and
NGY152 was shown to peak after 3 days growth in liquid cultures
(Supplementary Figure S2). Consequently, samples of 3-day-old
culture fluids from wild-type and mutant strains of C. albicans
were tested for recognition of extracellular antigens by MC3 in
ELISA tests (Figure 2D). There was no significant difference
in MC3 detection of extracellular antigens from the wild-type
strains SC5134 and NGY152, and mutants 1och1, 1mnn4, and
1mnt1,2. However, there was a significant reduction in binding
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FIGURE 1 | Specificity of mAb MC3 determined by Enzyme-Linked Immunosorbent Assay tests of surface washings containing water-soluble antigens from
Candida species and related and unrelated yeasts and molds. ELISA absorbance values at 450 nm for soluble antigens from Candida species in the CTG clade and
Saccharomycetaceae, the emerging human pathogen Candida auris (inset), and other related and unrelated yeasts, yeast-like fungi and molds of clinical
significance. Wells were coated with 60 µg protein/mL buffer. Bars are the means of three biological replicates ± standard errors and the threshold absorbance value
for the detection of antigen is ≥0.1 (indicated by line on graph).
of MC3 to extracellular antigens from 1pmr1 compared with
the other mutants and wild-type strains. Western blotting studies
conducted with the same samples (Figure 2E) showed that
MC3 reacted strongly with high molecular weight extracellular
antigens, but the staining pattern with 1pmr1 was markedly
different to the other strains. Furthermore, the ∼12 kDa antigen
present in surface washings of NGY152, 1och1, 1mnn4, and
1mnt1,2 (Figure 2C) was only present in culture fluids with
mutant1mnt1,2 (marked with asterisk in Figure 2E).
Epitope Characterization by Heat,
Chemical, and Enzymatic Modification
Candida albicans SC5314 antigens were subjected to
heat (Figure 2F), periodate (Figure 2G), and enzymatic
(Supplementary Table S2) treatments to further elucidate the
epitope bound by MC3. Reductions in mAb binding in ELISA
following heat treatment would indicate that its epitope is heat
labile. However, there was no significant reduction in MC3
binding over 60 min of heating, showing that its epitope is
heat stable (Figure 2F). Reductions in mAb binding following
chemical digestion with periodate shows that its epitope is
carbohydrate and contains vicinal hydroxyl groups. Significant
reductions in MC3 binding were observed after 1 h of periodate
treatment (Figure 2G), showing that its epitope consists of
carbohydrate moieties. Reductions in mAb binding following
treatment with pronase shows that its epitope consists of
protein, while reductions with trypsin indicate a protein epitope
containing positively charged lysine and arginine side chains.
Consequently, the lack of reduction in MC3 binding following
digestion of immobilized antigen with pronase or trypsin
confirmed that the antibody does not bind to a protein epitope
(Supplementary Table S2).
Immunofluorescence
Immunofluorescence studies showed that the MC3 antigen is
present on the cell wall surfaces of C. albicans blastospores
(Figures 2H–K), and hyphae (Figures 2J,K) of C. albicans.
The lack of fluorescence of control samples (Figures 2L,M)
further demonstrates the specificity of mAb MC3 for the different
morphotypes of the pathogen.
PET/MR Imaging of Invasive Candidiasis
Using [64Cu]NODAGA-MC3
For immunoPET imaging, MC3 was conjugated with the chelator
NODAGA. The conjugated antibody was then labeled with the
radionuclide 64Cu, which allows consecutive imaging for up
to 3 days. The specific activity of the [64Cu]NODAGA-MC3
tracer used in the in vivo bio-distribution studies was determined
to be in the region of 620-770 MBq/mg at the time point of
injection. Radiochemical purity (TLC) was 95.4%. The serum
stability of the [64Cu]NODAGA-MC3 tracer was determined by
iTLC and radio-HPSEC, with the analysis showing no concerning
signs of proteolytic degradation, protein aggregation, or copper
transchelation to serum proteins over a 48 h time period
(Supplementary Figure S4).
Mice were given tail vein injections with blastospores of
C. albicans or C. auris and the [64Cu]NODAGA-MC3 tracer,
and bio-distributions evaluated by simultaneous PET/MRI at
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FIGURE 2 | Characterisation of the MC3 antigen, its epitope and spatial distribution in yeast and pseudohyphal cells. (A) ELISA absorbance values at 450 nm for
purified C. albicans cell wall mannan. Each point is the mean of three replicates ± standard errors. (B) Western immunoblot with MC3 using purified C. albicans cell
wall mannan (Mannan) and soluble antigens extracted from immunogen of C. albicans SC5314 (SC5314). Wells were loaded with 1.6 µg of protein. Mr denotes
molecular weight in kDa. (C) Western immunoblot with MC3 using soluble antigens in surface washings of the C. albicans wild-type strain NGY152 and the mannan
mutant strains. Wells were loaded with 1.6 µg of protein. The asterisk (∗) indicates the low molecular weight band of ∼12 kDa, assumed to be PLM, which is absent
in extracts from the 1pmr1 mutant. (D) ELISA absorbance values at 450 nm for culture fluids from the C. albicans wild-type strains SC5314 and NGY152 and the
mannan mutant strains. Wells were coated with 60 µg protein/mL buffer. Each bar is the mean of three biological replicates ± standard errors and bars with the
same letter are not significantly different at p < 0.001. (E) Corresponding western immunoblot with MC3 using culture fluids from the C. albicans wild-type strains
SC5134 and NGY152 and mannan mutant strains. Wells were loaded with 1.6 µg of protein. The asterisk (∗) indicates the low molecular weight band of ∼12 kDa
which is only present in culture fluids of the mutant 1mnt1,2. (F) ELISA absorbance values at 450 nm for heat-treated antigens from C. albicans SC5314. Wells were
coated with 60 µg protein/mL buffer. Each bar is the mean of three biological replicates ± standard errors and bars with the same letter are not significantly different
at p < 0.001. There was no significant effect of heating on MC3 recognition, indicating that its antigen is heat-stable. (G) ELISA absorbance values at 450 nm for
periodate-treated antigens (white bars) and control-treated antigens (gray bars) extracted from lyophilised cells of C. albicans SC5134. Wells were coated with 60 µg
protein/mL buffer. Each bar is the mean of three biological replicates ± standard errors and bars with different letters are significantly different from one another at
p < 0.001. The significant reduction over time of MC3 recognition of periodate-treated antigens shows that the antibody’s epitope is carbohydrate and contains
vicinyl hydroxyl groups. (H–M) Photomicrographs of C. albicans SC5314 blastospores and hyphae immunostained with MC3 (I,K) or TCM control only (M) followed
by anti-mouse polyvalent Ig fluorescein isothiocyanate conjugate. Bright-field images of C. albicans SC5134 blastospores (H) and blastospores and hyphae (J,L).
(I–M) Same fields of view as (H–L), but examined under epifluorescence. Scale bars = 4 µm. Note the intense staining of cell walls of blastospores and hyphae with
MC3 (I,K), but lack of staining with TCM only (M), demonstrating specific recognition of C. albicans yeast and hyphal cells by the antibody.
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3, 24, and 48 h post-infection. Representative images are
shown in Supplementary Figures S5A (3 h), S5B (24 h), and
Figure 3A (48 h), where the same mice are imaged at each
time point. Control mice were injected with PBS in place of
blastospores, but were otherwise treated similarly. PET imaging
showed uptake of the tracer in the left and right kidneys of
C. albicans-infected animals at 24 h (Supplementary Figure
S5B) and 48 h (Figure 3A) p.i., that was absent in the kidneys
of PBS control animals and animals injected with C. auris.
While there was considerable variability between animals, in vivo
quantification, expressed as %ID/cc (Figure 3B), showed that
uptake of the antibody tracer in the left and right kidneys was
significantly greater in C. albicans-infected animals compared
to PBS controls and C. auris-infected mice. At 24 h p.i., a
significantly higher %ID/cc of the [64Cu]NODAGA-MC3 tracer
was observed in the left and right kidneys of C. albicans-infected
mice (10.5 ± 0.8 and 10.8 ± 0.9 %ID/cc, respectively) compared
to PBS controls (left kidney: 6.5 ± 0.7 %ID/cc, right kidney:
7.5 ± 0.7 %ID/cc), and C. auris-treated animals (left kidney:
7.4 ± 0.3 %ID/cc, right kidney: 7.7 ± 0.8 %ID/cc). The
uptake of [64Cu]NODAGA-MC3 was found to be highest in
the left and right kidneys of C. albicans-infected animals 48 h
p.i. with 12.7 ± 6.3 and 12.3 ± 4.9 %ID/cc, respectively,
compared to the significantly lower uptake of the tracer in the
kidneys of PBS treated (left kidney: 5.7 ± 1.1 %ID/cc, right
kidney: 6.2 ± 0.8%ID/cc) and C. auris-infected (left kidney:
6.1± 0.8 %ID/cc, right kidney: 7.0± 0.8 %ID/cc) mice. Increased
uptake of the tracer was also found in the spleen (Supplementary
Figure S6A) and brain (Supplementary Figure S6B), but not
liver (Supplementary Figure S6C), of C. albicans-infected mice.
The uptake of [64Cu]NODAGA-MC3 was significantly higher
in the brain of C. albicans-infected mice 24 and 48 h p.i. with
2.1 ± 0.1 and 1.8 ± 0.2 %ID/cc, respectively, compared to PBS
controls (24 h p.i.: 1.7 ± 0.1 %ID/cc, 48 h p.i.: 1.5 ± 0.1 %ID/cc)
and C. auris-infected animals (24 h p.i.: 1.6 ± 0.1 %ID/cc,
48 h p.i.: 1.4 ± 0.1 %ID/cc). In all three organs, the trend in
%ID/cc was a gradual decline over time. Increased uptake of the
tracer was also found in the muscle tissues of C. albicans-infected
mice at 24 h, but this increase was not sustained at 48 h
(Supplementary Figure S6D). Results from in vivo PET imaging
were confirmed by the ex vivo biodistribution data (%ID/g)
at 48 h p.i. (Figure 3C), showing significantly higher uptake
of [64Cu]NODAGA-MC3 in the left and right kidneys of
C. albicans-infected mice (left kidney: 31.8 ± 13.3 %ID/g, right
kidney: 38.4 ± 17.8 %ID/g) compared to the PBS controls (left
kidney: 15.5 ± 1.6 %ID/g, right kidney: 16.1 ± 2.7 %ID/g), and
C. auris-infected animals (left kidney: 16.1 ± 1.6 %ID/g, right
kidney: 15.9 ± 1.8 %ID/g). Significant increases in tracer uptake
were also seen in the brain (C. albicans: 3.0± 0.7 %ID/g, C. auris:
1.5 ± 0.2 %ID/g, PBS: 1.5 ± 0.2 %ID/g), muscle (C. albicans:
4.6 ± 0.5 %ID/g, C. auris: 3.2 ± 0.1 %ID/g, PBS: 3.2 ± 0.3
%ID/g), and colon (C. albicans: 8.4 ± 2.1 %ID/g, C. auris:
5.7 ± 0.7 %ID/g, PBS: 5.2 ± 0.6 %ID/g) of C. albicans-infected
mice compared to PBS controls and C. auris-infected mice, while
there was a significant increase in uptake of the tracer in the
spleen of C. albicans-infected mice (22.2± 5.7 %ID/g) compared
to the C. auris mice (13.4 ± 2.2 %ID/g). There was a significant
reduction in the tracer content of blood of C. albicans-infected
animals (32.3± 3.1 %ID/g) compared to the PBS control animals
(41.0± 5.9 %ID/g).
Significant decreases in body weight after i.v. challenge were
found in mice injected with C. albicans, but there were no
significant decreases in the body weights of PBS control mice
and C. auris-infected mice over the study period (Supplementary
Figure S7).
DISCUSSION
Fungal infections of humans are responsible for at least
as many deaths as tuberculosis or malaria, with the most
common fungal pathogens (Aspergillus, Candida, Cryptococcus,
and Pneumocystis) infecting an estimated two million individuals
worldwide (Brown et al., 2012). Most of these infections are in
immunocompromised or critically ill patients, with C. albicans
the most common cause (up to 70%) of IC in ICU patients and
of recipients of transplanted abdominal organs (Calandra et al.,
2016), with an average mortality rate of 40%.
As with all invasive fungal diseases, diagnosis of IC is a
major challenge, but prompt and accurate detection is crucial
so that appropriate antifungal drug treatment can be started
rapidly. In diagnosing IC, three entities must be considered: (1)
candidemia without deep-seated candidiasis; (2) candidemia with
deep-seated candidiasis; and (3) deep-seated candidiasis without
candidemia. Culture of Candida from blood samples, considered
the gold standard diagnostic test for IC, is positive in only
50–70% of cases, is slow, and is rarely positive in patients with
deep-seated candidiasis (Clancy and Nguyen, 2013). Combined
determinations of Candida mannan (Mn) and anti-Mn (A-Mn)
antibodies using the Platelia Candida ELISA formats (Ellis et al.,
2009) is a useful aid in monitoring patients at high risk for
IC but relies on circulating antigen being present when a
blood sample is taken. The “pan-fungal” (1→3)-β-D-glucan test
is recommended as an indicator of invasive fungal infection
(Alexander et al., 2010; Lamoth et al., 2012) but the test
lacks specificity to Candida, cross-reacting with a number of
other yeasts and molds, including Trichosporon and Aspergillus
species, and so its use in detecting IC is limited (Pickering
et al., 2005; Karageorgopoulos et al., 2011). Attempts have been
made to track Candida infections in vivo, with Jacobsen et al.
(2014) recently reporting bioluminescence imaging for real-time
monitoring of IC in mice. While a powerful technique, it relies
on bioluminescent C. albicans reporter strains expressing firefly
luciferase, meaning that optical (bioluminescence) imaging can
only be performed using a single genetically modified strain of
the fungus, and is in general limited by the low tissue penetration
of light. In the clinical setting, [18F]FDG PET/CT has been used
to visualize IC and Candida lung abscesses (Bleeker-Rovers et al.,
2005; Avet et al., 2009), but its accuracy in identifying IC or
invasive fungal infections in general remains to be fully proven,
since the radiopharmaceutical is unable to discriminate between
infectious and non-infectious pathologies or to differentiate
between bacterial and fungal infections and inflammation (Rolle
et al., 2016). Nevertheless, a recent retrospective comparison of
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FIGURE 3 | (A) In vivo biodistribution of [64Cu]NODAGA-MC3 in PET/MR imaging at 48 h p.i. Coronal Maximum Intensity Projection (MIP), MR and fused PET/MR
images of PBS-treated (control) mice, and C. albicans-infected and C. auris-infected mice injected with the tracer. The acquired images reveal specific uptake of the
tracer in the left and right kidneys of C. albicans-infected mice, but not in the kidneys of PBS-treated (control) mice. The specificity of the tracer was further
demonstrated using a strain of C. auris which, while reactive with MC3 in vitro using ELISA (Figure 1), was non-infective in the i.v. challenge model. Here, uptake of
the tracer in the kidneys was similar to the uptake found in the PBS control mice. (B) Quantification of the PET images for the left and right kidneys of the three
different groups of mice at 3, 24, and 48 h p.i. Significantly higher uptake of the [64Cu]NODAGA-MC3 tracer is seen in the left and right kidneys of
C. albicans-infected mice compared to PBS-treated (control) and C. auris-infected animals at 24 and 48 h p.i. Data are expressed as mean ± SD %ID/cc. Group
differences were examined using one-way ANOVA, followed by post hoc Tukey–Kramer, with significant differences at ∗p < 0.05. (C) Ex vivo biodistribution at 48 h
p.i. Significantly higher uptake of the [64Cu]NODAGA-MC3 tracer in the left and right kidneys of C. albicans-infected mice, compared to the kidneys of corresponding
PBS-treated (control) and C. auris-infected animals, confirms the PET/MR imaging and in vivo biodistribution data at 48 h p.i. In addition to increased uptake of the
tracer in the kidneys, significantly higher uptake was also shown in the colons, muscles, and brains of C. albicans-infected mice compared to C. auris-infected and
PBS-treated mice, significantly higher uptake in the spleens of C. albicans-infected mice compared to C. auris-infected mice, but significantly reduced uptake in the
blood of C. albicans-infected mice compared to PBS-treated (control) animals. Data are the results of N = 4–5 animals per group and expressed as the mean ± SD
%ID/g.
Frontiers in Microbiology | www.frontiersin.org 10 August 2018 | Volume 9 | Article 1996
fmicb-09-01996 August 22, 2018 Time: 17:20 # 11
Morad et al. Antibody-Guided Imaging of Invasive Candidiasis
[18F]FDG PET/CT to conventional CT imaging has shown the
utility of [18F]FDG PET/CT as a non-invasive procedure for
monitoring responsiveness of Candida and mold infections to
antifungal drugs once the identity of the infecting organisms
has been established using conventional diagnostic procedures
(Douglas et al., 2018).
In this paper, we set out to improve the diagnostic accuracy
of PET-based imaging for invasive C. albicans candidiasis by
creating and testing a mAb-based tracer for tracking deep-seated
C. albicans infections in vivo. To this end, we report the
development and characterisation of a mannan-specific IgG3
mAb, MC3, and its use in antibody-guided positron emission
tomography and magnetic resonance (immunoPET/MR) of IC in
a pre-clinical mouse model of disease. Recently, we reported the
use of immunoPET/MR to image IPA caused by the ubiquitous
environmental mold A. fumigatus (Rolle et al., 2016; Davies et al.,
2017; Thornton, 2018), but this is the first time, to our knowledge,
that the potential of immunoPET/MRI to track deep-seated
C. albicans infections in vivo has been demonstrated, with the
potential for translation of the technology to the clinical setting
and human disease detection.
Monoclonal antibody MC3 was raised against a heat-stable
carbohydrate epitope on cell wall mannans of C. albicans yeast
and hyphal morphotypes. This is crucial from a diagnostic
perspective since C. albicans is a pleomorphic yeast, which
regularly switches morphologies during infection (Calderone and
Fonzi, 2001). The absence of the ∼12 kDa immunoreactive
antigen in the mutant1pmr1, which has massively reduced PLM,
very little O-mannan and a N-glycosylation defect, suggests that
the MC3 epitope consists of β-1,2-mannan residues (Trinel et al.,
1999; Mille et al., 2004; Fradin et al., 2008). This is consistent with
immunodominant (1→2)-β-mannan structures in C. albicans
PLM bound by the protective β-mannan-specific IgG3 mAb, C3.1
(Han et al., 2000; Johnson et al., 2012).
Specificity tests show that MC3 reacts with mannans from
several clinically important Candida species, but not with a wide
range of related and unrelated human pathogenic yeasts and
molds of clinical importance. The mAb was able to discriminate
C. albicans from the human yeasts C. glabrata, C. neoformans,
and T. asahii in polymicrobial cultures, a crucial property given
the emerging issue of mixed fungemia in critically ill patients
(Jensen et al., 2007; Miceli et al., 2011; Badiye et al., 2012;
Davies and Thornton, 2014; Yang et al., 2014). The Candida
species recognized by MC3 are all reported to cause IC (Morgan
et al., 1984; Leung et al., 2002; Hawkins and Baddour, 2003;
Pfaller et al., 2006, 2014; Jensen and Arendrup, 2011; Khan
et al., 2012; Beyda et al., 2013; Borman et al., 2016). C. albicans
is the most prevalent cause of IC worldwide and thus of
the highest clinical significance (Diekema et al., 2012; Guinea,
2014), but all of the other MC3-reactive species (C. auris,
C. dubliniensis, C. famata, C. guilliermondii, C. lusitaniae,
C. palmioleophila, C. pseudotropicalis, C. tropicalis) have emerged
as serious human pathogens (Morgan et al., 1984; Leung et al.,
2002; Hawkins and Baddour, 2003; Pfaller et al., 2006, 2014;
Jensen and Arendrup, 2011; Khan et al., 2012; Beyda et al., 2013;
Borman et al., 2016). A weakness of the mAb is its inability
to detect C. glabrata, C. krusei, or C. parapsilosis, which are
also important causes of IC, especially C. glabrata (Chi et al.,
2011; Papon et al., 2013; Pfaller et al., 2014). Consequently, while
MC3 reacts with a number of clinically relevant Candida species,
especially C. albicans, the most common cause of IC in humans,
its inability to detect all pathogenic species means that it would
need to be used alongside other diagnostic procedures in the first
instance.
Notwithstanding the issue of specificity, we have shown that
an anti-mannan mAb, MC3, can be deployed in a disease-specific
probe ([64Cu]NODAGA-MC3) to detect deep-seated C. albicans
infections in vivo, and have demonstrated the accuracy of
the antibody-guided approach to molecular imaging of IC
in the most commonly used, well-characterized, and reliable
experimental model of disease, the (i.v.) challenge model
(MacCallum and Odds, 2005; Conti et al., 2014). We used the
clinical isolate C. albicans SC5314 (to which mAb MC3 was
raised) for the pre-clinical immunoPET/MRI studies as it belongs
to the predominant clade of closely related C. albicans strains that
represents almost 40% of all isolates worldwide (Soll and Pujol,
2003). In addition to a PBS control group, we used, as a Candida
control, a strain of the emerging human pathogen Candida auris,
since this pathogen reacts with MC3 in in vitro ELISA tests, but
is non-infective in the i.v. challenge model. The reasons for this
lack of pathogenicity are unclear, but strain-specific differences
in pathogenicity are documented in this pathogen (Borman et al.,
2016).
Detailed studies of the i.v. challenge model using C. albicans
SC5314 (MacCallum and Odds, 2005; Conti et al., 2014)
have shown the overall course of infection of mice to be
elimination of the fungus from blood within 5–10 h, followed
by a sudden rapid growth of the fungus in kidney and
brain, and progressive elimination of fungus from liver, lung,
heart, and spleen. Loss of weight of animals after challenge
(cachexia) is a predictor of mortality in the i.v. challenge
model (MacCallum and Odds, 2005), as so we used this as
a proxy indicator of disease development in infected mice in
our study. Only the mice infected with C. albicans showed
cumulative and significant weight loss following injection of
the pathogen and tracer into the bloodstream, signifying the
establishment and progression of IC in these animals. Using the
two Candida strains and a PBS control group, we showed the
[64Cu]NODAGA-MC3 tracer to be highly accurate in detecting
deep-seated infections caused by C. albicans SC5314. PET
imaging showed sustained uptake of the [64Cu]NODAGA-MC3
tracer in the kidneys of C. albicans-infected animals at 24
and 48 h, which coincides with exponential growth of the
fungus in kidneys in the disease model (MacCallum and Odds,
2005; Conti et al., 2014). In vivo and ex vivo bio-distributions
of the tracer followed a trend similar to that of known
disease progression, with sustained uptake of the tracer in
the kidneys of C. albicans-infected mice at 24 and 48 h
p.i., as well as increased uptake in the brain. Uptake of
[64Cu]NODAGA-MC3 was observed in the liver of all treatment
groups, but this decreased over the course of the study coincident
with progressive reduction in fungal burden in the i.v. challenge
model (MacCallum and Odds, 2005). The in vivo bio-distribution
data showed a steady accumulation of tracer in the spleen of
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C. albicans-infected animals over the 48 h experimental period,
while the ex vivo data showed a significant increase in uptake at
48 h compared to the PBS controls and C. auris-infected animals.
This is consistent with spleen infection, since the spleen is a
well-documented site of C. albicans infection during IC (Vazquez
and Sobel, 2011). The ex vivo bio-distribution data similarly
showed a significant increase in uptake of the tracer in the colon
and muscle of C. albicans-infected animals, albeit at markedly
lower levels than that of the kidneys. Previous studies using a
mouse model of IC demonstrated in vivo muscle infection caused
by C. albicans (Oblack et al., 1980), while infection of the colon
by C. albicans during IC has been shown both in mouse infection
models and in humans (Cole et al., 1996; Praneenararat, 2014).
There were no significant differences in uptake of the tracer in
the heart, lung, and stomach of the three experimental groups.
These organs are known to be non-infected by C. albicans in the
i.v. challenge model (MacCallum and Odds, 2005). The recurring
detection of the pathogen in the blood (candidemia) after 24 h of
infection with a high infection dose of C. albicans was reported in
the i.v. challenge model (MacCallum and Odds, 2005). Here, we
found a lower uptake of [64Cu]NODAGA-MC3 in the blood of
C. albicans-infected mice at 48 h p.i. compared to the PBS control
and C. auris-challenged mice. This phenomenon likely resulted
from the significantly higher uptake of the tracer in the kidney,
spleen, brain, colon, and muscle tissues of theC. albicans-infected
mice, thereby reducing the amount of unbound tracer in the
bloodstream.
CONCLUSION
We have shown that antibody-guided molecular imaging
(immunoPET/MRI) can be used to detect disseminated infection
caused by C. albicans, the most important cause of IC in humans.
Using a well-established animal model of infection, which
faithfully mimics the disease in humans, we have shown that the
[64Cu]NODAGA-MC3 tracer provides a highly accurate means
of detecting kidney, brain, and spleen infections in vivo. As the
principal sites of deep organ infection in humans (Vazquez and
Sobel, 2011), sensitive and specific detection of C. albicans in
these organs is of paramount importance for timely diagnosis and
treatment. A limitation of our work is the short time period over
which sequential monitoring of pathogen distribution could be
determined after injection with the [64Cu]NODAGA-MC3 tracer
(up to 48 h post-injection), and the use of an immunocompetent
mouse model of candidiasis. This might explain why we did
not detect Candida infective endocarditis or hepatosplenic
candidiasis (although significantly higher uptake of the tracer
was found in the spleens of C. albicans-infected mice) which,
while relatively rare (Halkin and Ksontini, 2007; Yuan, 2016), are
nevertheless important clinical manifestations of disseminated
Candida disease in humans with associated high mortality
rates. Since hepatosplenic candidiasis is most common in
immuno-compromised patients (Halkin and Ksontini, 2007),
an alternative animal model of candidiasis would need to be
used that mimics these diseases in immune-depleted individuals
(Conti et al., 2014). Adapting the i.v. challenge model used
here might allow the accuracy of the tracer in detecting a
previously established infection to be determined. Such a strategy
is shown in Supplementary Figure S3B where, rather than
simultaneous injection of blastospores and tracer, the fungal
inoculum is injected 24 h prior to tracer injection to allow a
systemic infection to first be established. However, we opted
to administer the pathogen and tracer simultaneously, as we
believed this would minimize stress to the animals, while at the
same time allowing the potential of antibody-guiding imaging of
IC to be investigated.
In order to develop an antibody-guided tracer that specifically
detects all Candida species of clinical importance, a mAb would
need to be developed that binds to an antigenic determinant
common to all Candida species, but which is not conserved in
other pathogenic yeasts and molds. Furthermore, such an epitope
would need to be absent in humans to prevent non-target binding
of the mAb to human structures. Our approach to IC detection
is essentially translatable to the clinical setting, since the mAb,
MC3, binds to a fungal carbohydrate (mannan) and epitope (a
putative β-1,2-mannan) which are not found in humans (Barreto-
Bertger and Figueirredo, 2014), thereby reducing substantially
the likelihood of adverse events using a humanized version of the
antibody tracer. The antibody and its mannan target therefore
represent excellent candidates for non-invasive detection of IC
in humans caused by C. albicans, the most common cause of IC
in humans. Translation of the mAb-based tracer to the clinical
setting will require humanisation of the mouse antibody using
CDR grafting technology similar to that recently used by our
group for humanisation of the Aspergillus-specific mAb JF5 for
diagnosis of IPA (Davies et al., 2017).
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